|
![]() |
|
|
EMLA: profile and news
HUNGRY GARDENER - Stock options Feb 23, 2006 Routine Inhaled Induction in Adults: A Safe Practice? Feb 14, 2006 A Comparison of a Needle-Free Injection System for Local ... Jan 29, 2006 What the experienced hands of plastic surgeons can do... Jan 24, 2006 Journal of the American Podiatric Medical Association Nov 29, 2005 AstraZeneca Provides Additional Support to Hurricane Victims Nov 17, 2005 AstraZeneca Provides Additional Support to Hurricane Victims Nov 17, 2005 AstraZeneca Pledges More Than $1 Million in Contributions and ... Sep 1, 2005 AstraZeneca Pledges More Than $1 Million in Contributions and ... Sep 1, 2005 State has standards for safe body piercing Aug 23, 2005 Joint Panel Review of the Eastmain-1-A and Rupert Diversion ... Aug 2, 2005 Rawi Competition To Develop Islamic Culture, Knowledge Jul 4, 2005 Lifeline ; News in Brief Jun 17, 2005 Lifeline ; News in Brief Jun 17, 2005 Small pleasures May 19, 2005 AJ Nye Back in Hospital Mar 1, 2005 Other information Indication For use as Dermal anesthesia Pharmacology Lidocaine is an anesthetic agent indicated for production of local or regional anesthesia and in the treatment of ventricular tachycardia occurring during cardiac manipulation, such as surgery or catheterization, or which may occur during acute myocardial infarction, digitalis toxicity, or other cardiac diseases. The mode of action of the antiarrhythmic effect of Lidocaine appears to be similar to that of procaine, procainamide and quinidine. Ventricular excitability is depressed and the stimulation threshold of the ventricle is increased during diastole. The sinoatrial node is, however, unaffected. In contrast to the latter 3 drugs, Lidocaine in therapeutic doses does not produce a significant decrease in arterial pressure or in cardiac contractile force. In larger doses, lidocaine may produce circulatory depression, but the magnitude of the change is less than that found with comparable doses of procainamide. Mechanism Of Action Lidocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses thereby effecting local anesthetic action. Drug Category Antiarrhythmic Agents; Anesthetics; Antiarrhythmic Agents; ATC:C01BB01; ATC:C05AD01; ATC:D04AB01; ATC:N01BB02; ATC:R02AD02; ATC:S01HA07; ATC:S02DA01 Brand Names/Synonyms Lignocaine; Cappicaine; Maricaine; Leostesin; Gravocain; Esracaine; Anestacon; Duncaine; Isicaina; After Burn Double Strength Gel; After Burn Double Strength Spray; After Burn Gel; After Burn Spray; Alphacaine; Anestacon Jelly; Dalcaine; DermaFlex; Dilocaine; Emla; L-Caine; Lanabiotic; Lidocaine; Lidoderm; Lidoject-1; Lidoject-2; Norwood Sunburn Spray; Octocaine; Octocaine-100; Octocaine-50; Rocephin Kit; Xylocaine; Xylocaine 5% Spinal; Xylocaine Dental Ointment; Xylocaine Endotracheal; Xylocaine Test Dose; Xylocaine Viscous; Xylocaine-MPF; Xylocaine-MPF with Glucose; Xylocard; Zilactin-L Dosage Forms CREAM; GEL; IMPLANT; JELLY; KIT; LIQUID; OINTMENT; SOLUTION; SPRAY Absorption Information derived from diverse formulations, concentrations and usages reveals that lidocaine is completely absorbed following parenteral administration, its rate of absorption depending, for example, upon various factors such as the site of administration and the presence or absence of a vasoconstrictor agent. Interactions Interactions for Lidocaine: The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension. Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine. Concurrent use of these agents should generally be avoided. In situations when concurrent therapy is necessary, careful patient monitoring is essential. Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. Chemical IUPAC Name 2-diethylamino-N-(2,6-dimethylphenyl)-ethanamide Chemical Formula C14H22N2O Half Life 109 minutes Drug Type Approved Drug # Accession No APRD00479 CAS Registry Number 137-58-6 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |